Takeda gains approval in Brazil for Qdenga

14 March 2023

Japan’s largest drugmaker Takeda (TYO: 4502) has revealed that its dengue vaccine, Qdenga (dengue tetravalent vaccine [live, attenuated]; TAK-003), is now approved by Brazil’s National Health Surveillance Agency (ANVISA) for the prevention of dengue caused by any of the four virus serotypes that can be found in individuals from four to 60 years of age.

The use of Qdenga should be in accordance with official recommendations of the regulatory agency. Qdenga is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing.

Takeda has succeeded in the dengue space where others have failed, such as French pharm major Sanofi (Euronext: SAN) with its Dengvaxia vaccine imploding amid a public health scandal about its safety in late 2017. Qdenga has also received approval in Europe, the UK and Indonesia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical